CA209-040: Nivolumab With Promising Safety and Antitumor Activity in Advanced HCC

May 29-June 2, 2015; Chicago, Illinois
Results of a phase1/2 study of nivolumab monotherapy in patients with advanced hepatocellular carcinoma reveal encouraging 12 month survival rate
Format: Microsoft PowerPoint (.ppt)
File Size: 479 KB
Released: May 31, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

From Clinical Care Options (CCO), watch a CME-certified video from a symposium at AASLD 2019 featuring expert perspectives on evolving systemic therapy for HCC

Richard Finn, MD
Program Director
Anthony El-Khoueiry, MD Josep M. Llovet, MD Andrew X. Zhu, MD, PhD, FACP
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: January 7, 2020 Expiration: January 6, 2021

Clinical Care Options (CCO) downloadable patient resource guide to help patients and their caregivers manage their treatment for head and neck cancer.

Released: January 3, 2020

Matthew Gubens, MD, MS, provides expert insight on frontline combination regimens using immunotherapy in advanced NSCLC.

Matthew Gubens, MD, MS Released: December 30, 2019

Results from ATEMPT trial of adjuvant trastuzumab emtansine (T-DM1) and paclitaxel/trastuzumab (TH) in stage I HER2-positive BC from SABCS 2019 as reported by Clinical Care Options (CCO)

Released: December 19, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?